title: Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer.
abstract: HER-2/neu (c-erbB-2) oncoprotein is a transmembrane glycoprotein and may function as a growth factor receptor being involved in the regulation of cell growth and cell transformation. We performed an analysis of 100 patients with endometrial cancer stage FIGO I to IV using an immunoperoxidase technique on formalin-fixed, paraffin-embedded tissue samples in order to determine HER-2/neu oncoprotein expression. HER-2/neu oncoprotein was expressed in the tumors of 21 patients (21%). Clinical stage, histologic stage, histologic grade and death of invasion did not correlate with HER-2/neu oncoprotein expression. We found HER-2/neu oncoprotein in all clinical stages and therefore it does not seem to be a late event in the natural history of endometrial cancer. HER-2/neu oncoprotein expression was associated with poor overall survival (log-rank P-value 0.04).
authors.affiliation: Department of Gynecology, Vienna University Medical School, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Kohlberger
authors.forename: A
authors.initials: A
authors.lastname: Loesch
authors.forename: H
authors.initials: H
authors.lastname: Koelbl
authors.forename: G
authors.initials: G
authors.lastname: Breitenecker
authors.forename: C
authors.initials: C
authors.lastname: Kainz
authors.forename: G
authors.initials: G
authors.lastname: Gitsch
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016889:Endometrial Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D012189:Retrospective Studies; D013194:Staining and Labeling; D016019:Survival Analysis
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases